Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2018. Refer to TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | glecaprevir/pibrentasvir (Maviret®) | ||
| Formulation | 100 mg/40 mg film-coated tablet | ||
| Reference number | 3007 | ||
| Indication | Treatment of chronic hepatitis C virus (HCV) infection in adults |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1917 | ||
| NMG meeting date | 06/09/2017 | ||
| AWMSG meeting date | 11/10/2017 | ||
| Date of issue | 19/10/2017 | ||
| NICE guidance | TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C (external website - opens in new window) |
||
| Commercial arrangement | PAS | ||